Insmed Incorporated INSM
104.44 USD -4.87 (-4.46%)
At closeNov 3, 2026, 4:42 PM EST
104.44 0.00 0.00%
After hours · Nov 3, 4:42 PM ET
104.30 Day range 111.11
90.39 52-week range 212.75
- YTD
- -39.99%
- 1 year
- -43.92%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 194.18 +85.9% upside
Now 104.44
- Target (low)
- 158.00
- Target (mean)
- 194.18
- Target (high)
- 243.00
Ratings (0m) 24 23 buy · 1 hold · 0 sell
- Strong buy5
- Buy18
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 24
- 1 month ago 24
- 2 months ago 24
- 3 months ago 23
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.33791 | -0.89 – -0.02024 | -1.54 | +78.1% | 597.94M | +126.6% | 16 |
| Next quarter | -0.28 | -0.53 – -0.06 | -0.76 | +63.2% | 625.63M | +104.5% | 6 |
| Current year | -1.74 | -2.17 – -1.31 | -6.42 | +72.9% | 1.86B | +206.6% | 15 |
| Next year | 0.58346 | -0.82 – 2.02 | -1.74 | +133.5% | 3.00B | +61.2% | 16 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Guggenheim | Maintained | Buy | Buy |
| Oct 21, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 12, 2026 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Oct 12, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 30, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 15, 2026 | Roth Capital | Reiterated | Buy | Buy |
| Aug 10, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 10, 2026 | Truist Securities | Reiterated | Buy | Buy |
| Aug 7, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 7, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 7, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jul 21, 2026 | BMO Capital | Initiated | — | Outperform |
| Jul 15, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 10, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Jun 22, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jun 8, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jun 5, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 14, 2026 | Truist Securities | Maintained | Buy | Buy |
| May 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 8, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| May 8, 2026 | Guggenheim | Maintained | Buy | Buy |
| Apr 17, 2026 | Roth Capital | Reiterated | Buy | Buy |
| Apr 14, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 1, 2026 | Barclays | Maintained | Overweight | Overweight |
| Mar 30, 2026 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Mar 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 25, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Mar 24, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Mar 24, 2026 | Stifel | Maintained | Buy | Buy |
| Mar 24, 2026 | Wells Fargo | Maintained | Overweight | Overweight |